Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) was the recipient of some unusual options trading activity on Wednesday. Stock traders bought 30,530 call options on the stock. This is an increase of approximately 937% compared to the typical daily volume of 2,944 call options.

Several brokerages have recently issued reports on ALNY. Cowen and Company reaffirmed a “buy” rating and issued a $100.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Tuesday, July 11th. Jefferies Group LLC set a $102.00 price objective on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, August 25th. Barclays PLC lifted their price objective on shares of Alnylam Pharmaceuticals from $50.00 to $70.00 and gave the stock an “equal weight” rating in a research note on Thursday, August 10th. Credit Suisse Group lifted their price objective on shares of Alnylam Pharmaceuticals from $90.00 to $96.00 and gave the stock an “outperform” rating in a research note on Tuesday, June 27th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $99.00 price objective (down previously from $105.00) on shares of Alnylam Pharmaceuticals in a research note on Wednesday, September 6th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and fourteen have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $93.11.

Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at 113.80 on Friday. The firm’s market capitalization is $10.44 billion. The company’s 50 day moving average is $81.14 and its 200 day moving average is $69.12. Alnylam Pharmaceuticals has a 12-month low of $31.38 and a 12-month high of $118.40.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.22) by ($0.12). Alnylam Pharmaceuticals had a negative return on equity of 45.53% and a negative net margin of 670.81%. The business had revenue of $15.93 million for the quarter, compared to the consensus estimate of $23.86 million. During the same period in the previous year, the company posted ($1.05) earnings per share. Alnylam Pharmaceuticals’s revenue for the quarter was up 82.9% compared to the same quarter last year. On average, analysts forecast that Alnylam Pharmaceuticals will post ($5.19) earnings per share for the current year.

In other Alnylam Pharmaceuticals news, President Barry E. Greene sold 76,815 shares of the firm’s stock in a transaction dated Wednesday, September 20th. The shares were sold at an average price of $100.00, for a total transaction of $7,681,500.00. Following the transaction, the president now owns 165,399 shares of the company’s stock, valued at approximately $16,539,900. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 4.30% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of ALNY. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Alnylam Pharmaceuticals during the 1st quarter worth approximately $148,000. QS Investors LLC increased its stake in Alnylam Pharmaceuticals by 59.7% during the 2nd quarter. QS Investors LLC now owns 2,408 shares of the biopharmaceutical company’s stock worth $192,000 after purchasing an additional 900 shares in the last quarter. Westpac Banking Corp bought a new stake in Alnylam Pharmaceuticals during the 1st quarter worth approximately $202,000. The Manufacturers Life Insurance Company increased its stake in Alnylam Pharmaceuticals by 7.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock worth $203,000 after purchasing an additional 167 shares in the last quarter. Finally, Prudential Financial Inc. bought a new stake in Alnylam Pharmaceuticals during the 1st quarter worth approximately $215,000. 94.25% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2017/09/22/alnylam-pharmaceuticals-target-of-unusually-high-options-trading-alny.html.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.